SPEECH BY PRESIDENT EMMANUEL MACRON FROM THE AGUETTANT FACTORY IN ARDÈCHE.

France Emmanuel Macron · President of France

13 June 2023 · Aguettant factory, Ardèche, France

Context
Macron addressed officials and industry leaders at the Aguettant pharmaceutical factory in Ardèche on June 13, 2023, highlighting France's reindustrialization and pharmaceutical sovereignty efforts.
Main themes
Pharmaceutical sovereignty, reindustrialization, decarbonization, medicine supply chain dependence, France Relance and France 2030, active pharmaceutical ingredient relocation, industrial job creation, European pharmaceutical imports, mid-sized enterprise development, Covid-19 lessons, climate and industry convergence
Duration
~37 min
89th percentile
Words
4,498
89th percentile
Sentences
176
86th percentile
Readability
39
35th percentile
Grade
14.0
67th percentile
Syntax
3.19
72nd percentile
Vocabulary
2.25
62nd percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 57%56%
  • Social 25%25%
  • Ceremonial 10%10%
  • Institutional 6%6%
  • Geopolitical 2%2%
  • Environmental 1%1%
  • Technological 0%0%
  • Not in focus 1%

176 sentences in 40 paragraphs

Ladies and gentlemen ministers,

Mr. Prefect,

Ladies and gentlemen parliamentarians,

Mr. President of the Departmental Council,

Mr. Mayor,

Ladies and gentlemen elected officials,

Mr. President of the Aguettant group,

Mr. Director,

Ladies and gentlemen, in your ranks and capacities,

Ladies and gentlemen.

Thank you very much first for welcoming us to this site, here in your municipality, Mr. Mayor; at this production site at the heart of a century-old family business in which massive investments have been made in recent years, which we commend and will continue to support as we have done in recent years. I wanted to express this to you with great emphasis.

Indeed, the years we have just gone through, and I want to place what we have experienced together here and thank you again for this visit; the choices that have been made, what our country, what our Nation, what our Nations have experienced with the Covid crisis, is that we have collectively experienced dependence. We have collectively become aware of this industrial dependence, which is never good in general and which is even less understandable and acceptable to our fellow citizens when it affects health and medicines. This dependence, we know, is particularly marked with respect to extra-European imports: 60 to 80% of active pharmaceutical ingredients (APIs) are produced in Asia, and 40% of medicines marketed in the European Union are imported. That is the reality of the numbers.

So, starting in 2020, we decided to react in Europe and particularly in France: you are the perfect illustration of this with France Relance and then France 2030. The entire sector, notably the major industrial projects and those of your laboratory, have been supported and have already allowed for the relocation and resolute development of production chains. This includes the development of seven products, the addition of a pre-filled syringe line at the Champagne site, and an ampoule manufacturing line at the Gerland site, and soon, the addition of a high-speed production line allowing for a quadrupling of the company's capacity for the production of bottled medicines and the development of new emergency and resuscitation medicines ready for use.

You have opened a new site in Gerland, created new production lines here in Champagne, and today, in addition to serving the French market, you export to a hundred countries. You mentioned impressive figures regarding developments over the past three years and the years to come in this regard. Furthermore, I want to reiterate that you participated, alongside the ministers, in the rescue of the company Carelide with the company Delpharm, and this takeover will ensure the sustainability of French production of infusion bags and paracetamol with the financial support of the State, but it was still necessary to have industrial players willing to take that risk.

All this to say that we are here in a company that illustrates the relevance of these aid mechanisms, the collective awakening of the need to recreate industrial independence in the field of medicine and treatments, the rescue of companies in the sector, and which serves as a model for our mid-sized enterprises (ETIs), industries that we want to continue to develop.

Indeed, the challenge, as we have reminded ourselves in recent weeks, is first and foremost to win the battle. Ultimately, the three battles that, for me, converge and are essential: reindustrialization, regaining sovereignty, and decarbonization. They converge, and we had a perfect illustration of this, which you described very well. Why, for years, did we allow production in your sector to be relocated? Because there was not enough yield in France, because there had been policies that were not always coherent, and because we allowed certain parts of our industry that were more polluting, that were less adapted to collective choices, and that were sometimes less profitable to go elsewhere.

Now, we are deciding to regain industrial sovereignty, particularly in the pharmaceutical field. In doing so, we are recreating industrial jobs: you have already gone from 90 to 140 employees here, and you will continue to grow. We are decarbonizing because the syringe packaging we saw earlier allows for significant savings, meaning these are more environmentally friendly packaging. It reduces the logistics chain, helps avoid waste, and it is under these conditions that we can become profitable again and regain industrial sovereignty over medicines.

Sovereignty, reindustrialization, the battle for the climate, and decarbonization. This triptych is what we pursue in all sectors, with the macroeconomic and sectoral choices we have made in recent years. While our country destroyed 1 million jobs in the industrial sector during the first 15 years of this century; since 2017, we have recreated 1,700,000 jobs. And in the strict sense of industry, we have already recreated at least 80,000 jobs. Where we had, between 2008 and 2016, due to the shock of the crisis, lost 600 factories, including 60 in your region, particularly in the health sector, it must be said, we have moved from first to fifth place in Europe. We have been able to catch up nearly half of the delay. We have already caught up, and we have recreated more than 300 net jobs.

So, reindustrialization is not just a concept. It is at work because we have made reforms, because we have made collective choices, because we have decided to invest, and we have shown that there is no inevitability. Simply, we are not recreating the same industry as yesterday. We are making choices, we are deciding to create a higher value-added, more decarbonized industry, and it is at this price, if I may say so, with this strategic clarity, that we can succeed in achieving our objectives. This is why unemployment has decreased, why we have never had so many apprentices, why we have never had such low youth unemployment alongside such participation in the labor market, and why we are, for the fourth consecutive year, the top destination for foreign investments.

This macroeconomic landscape is particularly true in the pharmaceutical sector. I said it, this field, that of medicines, is perhaps one of the most spectacular in terms of sovereignty because it is one of the sectors for which the loss of sovereignty is the most intolerable. Delegating to others the responsibility of producing essential medicines in a fragmented world is a dead end. We experienced this during a health crisis, and we could be led to experience it again, which is why we must double our efforts here.

Doubling our efforts, and that is what we have done, is first and foremost about innovating in ecosystems. This is the purpose of the investments in research and innovation that we have decided upon with the programming law for research that was passed in the first five-year term, with France 2030 and more than 50 billion euros in investment, and with the ten new IHU and bioclusters across France that I announced a few weeks ago at the Curie Institute. Thanks to this, we will be able to develop new therapies in France, ranging from messenger RNA therapies to anticancer drugs, and for the most innovative medicines, this is the whole purpose of the direct access measures that are also at the heart of the health innovation strategy we have prepared thanks to all of you. Having a strong innovation strategy, putting resources into it, simplifying, accelerating our mechanisms, and then maintaining what is a French strength, which is to ensure access for all to medicines, because we are committed to this model, and therefore to both classic, historical medicines, but also to the most recent medicines, sometimes still in development, we want there to be access for all.

And then alongside this innovation in ecosystems regarding medicines, we have decided to relocate critical medicines, to relocate the production of certain strategic medicines. This is why we launched massive actions as early as 2018 — and even more so with the Covid crisis. This is also why I committed strongly to this issue during the last presidential campaign.

With France Relance, we have massively strengthened our supply chains. Thus, more than 100 projects concerning medicines and vaccines and contributing to strengthening the value chain of medicines have been supported, ranging from in vitro diagnostic tests to the vaccine value chain to enable France to ensure the filling of an additional 660 million doses per year.

With real results again, and I want to thank all the industry players who participated, the relocation of the production of the active ingredient of paracetamol in France in stages, the production of masks, or even medicines from blood plasma in Arras, IPSEN investing 40 million euros at the Signes site in Var to relocate the production of anticancer drugs, Pierre FABRE relocating the entire production chain from the active ingredient to the packaging of Braftovi-Mektovi, Sanofi choosing France to establish new capacities and expertise in Neuville, Marcy, or Sisteron, and many others. This dynamic is underway, and thus this policy of innovation and relocation is working and attracting foreign investors from the pharmaceutical sector. This was very well demonstrated again by Choose France a few weeks ago, but they only come because they see French and historical players, new players developing and carrying projects throughout the territory. This is what convinced the American Pfizer to invest an additional 500 million euros per year in R&D and production. This is the Italian Chiesi in Chaussée-Saint-Victor to produce the next generation of inhalation devices with a lower carbon footprint, the Danish Novo Nordisk in Chartres, the British GSK, AstraZeneca a few years ago, and many more. All this strengthens the support of our historical pharmaceutical companies, those of G5 Pharma and their 53 factories that represent 20,000 employees and 1 billion euros in industrial investments each year. And it also includes all the ETIs, including Aguettant, of course, CDMO, and others in the sector, which we sometimes discovered during the Covid crisis and which help us produce these vaccines, Delpharm, Fareva, and many others. It also helps to consolidate the dynamic of biotech and medtech start-ups that are developing, DNA Script, Lifen, Osivax, Trifrog, ImCheck. You know, I am not one of those who oppose start-ups to ETIs or large groups. It is a continuum, and we need to strengthen and accelerate innovations because they feed off each other.

We have thus succeeded in this phase of catching up, sometimes even taking the lead in certain segments. Now, we need to go further. And that is what I came to tell you today. First, in terms of innovation, by accelerating, this is the whole purpose of the IHUs and bioclusters in particular, which will lead to an unprecedented public-private investment, which is a phase of massive acceleration across the territory. I provided the details a few weeks ago, but I am really counting on all the industry players to invest massively because we have, I believe, all the major future verticals represented there: with the Health Innovation Agency developing support for innovative start-ups, simplifying clinical trials, and mass purchasing of innovative technologies. And so, beyond investments, we must continue to improve our ecosystem, go much faster on authorizations, on preclinical phases, clinical phases, and development phases, and allow for a much more cooperative ecosystem between innovators, industrial development, and regulators. In this regard, I have given very clear orders with a six-month horizon.

Next, we must continue to develop innovative medicines in France to achieve the goal we have set of 20 biomedicines in France. We already have 5 today and about twenty in clinical trials. And so, we can absolutely achieve this result, but we must continue to move forward, to accelerate even more.

Next, there is the big question of relocations. As I mentioned, the dynamic has entered a defensive phase. We sometimes started to get ahead, but now we need to systematize things. So, we will first stabilize a unique list of essential medicines to treat our fellow citizens, which we will evaluate according to the risks of shortages, and establish a monitoring system for these products and risk management measures, allowing the ANSM to impose sanctions if regulatory measures are not respected. This list will be evolving and will be detailed this afternoon by the minister. It includes 450 medicines. It is therefore not fixed, but it is already a very important list because it will concentrate our efforts. The minister will detail it. This is an important first step towards achieving our goal of securing the supply chains of these molecules at the French-European level. And fundamentally, for these 450 already identified medicines, we say we cannot afford to have weaknesses. Therefore, what we sometimes experienced during the Covid crisis and sometimes in recent months regarding some of these medicines must not be repeated. Thus, in the months and years to come, we must absolutely secure our supply chains for these 450 medicines, either by fully relocating or by diversifying and continuing to innovate.

Next, on a part — this is the heart of the reactors — of the products for which we identify a need to strengthen our sources of supply. Here, we must absolutely continue to relocate the raw materials or finished products, sometimes both, to secure the stock supply on the territory. And if I may say so, within these 450, there is a core list. When diversification is not enough, even when doubling our supply chain is not enough: we must relocate. That is why we have decided to accelerate, and in the coming weeks, I announce that out of the fifty essential medicines for which our dependence on extra-European imports is evident — thus the medicines to be relocated — half, that is to say 25 of these medicines, will see their production relocated or significantly increased on national territory. I had committed to 50, half of them in the coming weeks. We will finalize the plans, announcements, and investments to fully relocate the chain. Eight new relocation projects, each involving several molecules, are being supported by the State through France 2030 and will be launched, representing a total investment of over 160 million euros. Obviously, this concerns you first and foremost. This is what you have already started on the lines, and it will be systematized. The entire value chain of midazolam, which is essential for our anesthesia and resuscitation products, will thus be relocated, from inputs to finished products, which particularly affects you. The active ingredient, a curare used in intensive care, which was under significant pressure during the crisis, will also be completely relocated. The production of the finished product of this medicine has already been relocated as part of France Relance, and we will completely relocate the active ingredients. We are also strengthening the French production capacities of the active ingredient and finished product of morphine, and in the context of significant pressure on pediatric amoxicillin last winter, the State is supporting the strengthening of the capacities of the French site that produced in Mayenne, at GSK. We have also relocated the production of six anticancer drugs. You see, the decisions that will be announced in the coming days and weeks allow us to relocate, often the active ingredient, but beyond that, the production of 25 medicines that are at the core of this list of 450.

All the manufacturers supported under this plan are making significant commitments regarding supply security for the products whose production is thus relocated and strengthened, which also allows us to meet our commitments to our hospitals, our healthcare professionals, and our fellow citizens. And these projects, in a very concrete way, allow us to strengthen our health security, to anticipate, to limit tensions and supply risks, and they also manifest a new paradigm that we launched as early as 2018, a partnership between the State and the pharmaceutical industry. And I really want to thank all the manufacturers involved: GSK, Séquence, EuroAPI, Interior, SkyePharma, Benta Lyon, Matt Pharma, Aguettant, who are engaging with us in this new dynamic beyond the manufacturers already mentioned. And to sustain this new partnership, a dedicated portal for the relocation of essential medicines will also be launched in the very near future. It will support capacity extension or relocation projects to move much faster and in a much simpler way. It will finance the development of innovative and decarbonized production processes for all these medicines, which also helps to strengthen our competitiveness. And an initial envelope of 50 million euros will support the first projects beyond those I have already announced. This will allow us, with this single portal, to systematize the initiation with these 25 medicines I just mentioned. Concretely, this means that we want to continue to move forward faster and stronger, but also to pay the fair price for certain medicines when it is the essential condition to guarantee French production. I know that work is being finalized on this point, and I say it here, medicine is not the variable adjustment of our health budgets. We must be coherent.

We want seriousness for our fellow citizens, and therefore we need control, but we also want to provide visibility and have an industrial policy. To do this, we must be able to pay for innovation, pay for relocation, and also have a fair price that allows, in the long term, by providing visibility, to have the industrial fabric that must become ours again. This is the cost to pay to regain independence. I say this because it is the coherence of our policy. The same goes for pharmacy as for our food. When I hear the debates we can have right now, when people are led to believe that nothing has a price and that nothing has a cost, that there are no people producing here because we simply decide to dismantle the industrial fabric... No, we must be coherent, and therefore we need a policy of seriousness, of long-term investment, of political support, of supply and demand, both at the same time. We will continue to pay the price with clarity.

Finally, we must also carry this ambition of relocation and strengthening production capacities at the European level. This is what we launched as soon as the crisis began. France, being a coordinating member of the PIIEC health, a European project whose one of the axes aims to innovate to make the production of medicines on European production sites more competitive and greener. I think, for example, of the project carried out in this context by EuroAPI, which plans to increase the production capacities of several active ingredients on which we are very dependent, as I mentioned earlier, on Asian imports through innovative and decarbonized processes. I also think of the pharmaceutical package recently proposed by the European Commission to help us strengthen our common resilience, as we did with the HERA instrument. And here too, I say very clearly, we Europeans must be very coherent. We must first be coherent in terms of intellectual property. Yes, we must be demanding in times of crisis when there are choices to close certain markets, as we experienced during the Covid crisis. But we cannot weaken the attractiveness of Europe by threatening the framework and stability of intellectual property and making it less attractive than the United States or others. Therefore, we must be competitive, provide a stable and clear framework for all European and non-European manufacturers who want to develop here.

We must also define and support, as Europeans, an ambition and quantified objectives for the production of essential medicines on our soil to combine the efforts of member states to strengthen the competitiveness of our pharmaceutical companies and reduce supply tensions. Then, I wish to support the initiative taken by Belgium for a Critical Medicines Act that allows precisely to identify the critical elements of the sector, to invest in them, and to have a relevant aid policy, as we have done for critical European materials.

On these critical materials, we have decided, on rare metals, to have a policy of developing our sovereignty, to regain market shares; we must do this on the segments that are key in terms of pharmacy. We must continue, as you have understood, to stand firm to accelerate at the French and European levels.

Finally, and I will conclude on this point, we must continue to stand firm on the issue of shortages. So obviously, everything I just said aims to ensure that we no longer have shortages of medicines in the long term as we have experienced. This is a very complex issue, which is multifactorial, and cannot be solely Franco-French. The structural response is the one I just provided; it is to rethink our production chains, to recreate resilience, and to relocate certain parts, to innovate more at home to produce more and conduct research at home. But we know that we will still have emergency situations in the coming months and years, so we must prepare for them by taking stock of the winter we just went through, where, regarding paracetamol and amoxicillin, we acted very early thanks to a warning and monitoring system and good dialogue. We know, however, that the situation is difficult, so we must go further.

First, by strengthening even more than we have started to do prevention: the best way not to depend on certain products is to have a good prevention policy. We will continue to develop it; we will not let up. We must not let go of our basic prevention; it is prevention from school, regular diagnostics, and the daily actions we learned during the Covid pandemic and have somewhat relaxed, but everything that allows us to have a very simple prevention policy, which costs nothing for our social security, is a matter of civility and collective education. But it is what allows us to prevent epidemic peaks and reduce our consumption of medicines. I say this; it may seem like a truism, but it is essential because it results in fewer sick people and lower costs for social security.

Next, it is obviously the vaccination policy that we will continue to develop. I am obviously thinking of Covid, flu, and bronchiolitis in infants, and so we will continue to move forward with all the actors in the sector. On this last point, we have even decided, pending the validation of the effectiveness of medicines by the Haute Autorité de Santé, to make pre-orders. This is a prevention policy; we will continue to advance on vaccination because it helps avoid the consumption of medicines.

Then, when we are sick, we need a more reasonable use of medicines. Here too, we saw it last winter; these products are precious goods, and therefore we must have a responsible policy in this regard. In 1 out of 2 cases, we know that, for example, antibiotics prescribed in the community are used inappropriately. We must continue to have a serious policy on this point. It is a health issue as much as an economic and capacity issue; capacity because when it is prescribed and used inappropriately, it deprives the good use, if there is scarcity; economic because it means that we are wrongly reimbursing antibiotics that are misused; and health because it develops antibiotic resistance, which is a major issue for the years to come. I say this with great gravity; it is a subject we will address. Research has already begun, but we will continue to invest in it because in almost all developed countries, you will see that the major pandemics we will face and the significant health difficulties will often be linked to antibiotic resistance and the mechanisms of resistance and mutations that we have developed due to the misuse of medicines. France is not exemplary in this regard, and therefore we must continue the work, and I will expect ambitious measures within the framework of the roadmap of the Minister of Health and Prevention on this point, so that we can deploy very rigorous policies as early as next winter.

The last point I wanted to make concerns a winter epidemic management plan to ensure that we do not run out of medications and therefore look at the available stocks in all specialties. Here too, we must be able to pay the fair price for essential medications, which are key in pediatric care in particular, and negotiate additional supplies for the national territory based on the plans that will be defined. For the most critical cases, a white drug plan that can be activated in the event of a major crisis will be developed, as we know how to do for our structures. We must do the same for medications, to avoid the worst. You see, it is an entire policy of management, prevention, anticipation, and crisis management in terms of medications that we have developed. Because despite everything we are doing and accelerating in terms of relocation, we know that we will face difficulties in the months and years to come; we cannot completely rule it out, so we must prepare for it.

To enable the entire system to work in good coordination, we will also work towards better informing all actors in the chain — patients, doctors, pharmacists, wholesalers — and towards better distribution of deliveries by using existing data and actions to enhance transparency to prioritize the prescription of medications that are not under pressure and to quickly provide information to everyone and properly redirect things; work with pharmacists to anticipate tensions; better inform patients and have a very cooperative and partnership-oriented policy; better share data across the entire supply chain to optimize the production and distribution of medications with manufacturers, wholesalers, and pharmacists. This change requires, as you have understood, a collective awareness, a mobilization of all, particularly health professionals whom I want to acknowledge and thank here for all their efforts, but with whom we will continue to work on each of these points. I believe that this effort for better prevention, better use, and better organization is absolutely essential, and I count on everyone to build and launch the necessary changes in the months and years to come.

So, ladies and gentlemen, this is what I wanted to detail before you today. You see, this reindustrialization is underway, particularly in the pharmaceutical sector. These relocations that we have talked so much about show that we have reversed the course of history together in recent years. Where, for decades, it was thought that relocations were not simply a fatality but the French industrial destiny, we are showing that everywhere, and throughout the French territory, Mr. Mayor, you can testify to this, we are relocating sometimes things that we had stopped because we are investing, we are reforming, because we are making relevant collective, public, and private choices to regain sovereignty, reindustrialize, and decarbonize our economy. This is what will allow us to have a stronger health system, a stronger industry, and, I believe very deeply, a stronger country. Thank you.